Revere Pharmaceuticals
Dr. Silverman is the CEO and founder of Revere Pharmaceuticals. He served as General Counsel of Concert from 2007 to 2017, helping the company become public in 2014. Previously, Dr. Silverman was Associate General Counsel at Millennium Pharmaceuticals (now Takeda) and served in various legal roles at Vertex Pharmaceuticals and FMC Corporation. Dr. Silverman also lectures for the BIO Executive Training Programs.
Dr. Silverman started his career as a research chemist. He has over 20 US patents. Dr. Silverman received his BA degree from Lehigh University, his PhD from the U of New Mexico and did post-doctoral training in organic chemistry at Stanford University. He received his JD from Rutgers Law School.
This person is not in any offices
Revere Pharmaceuticals
Revere Pharmaceuticals is a Boston-based startup leading the way in the development of new cancer treatments targeting Rac1 GTPase, an important target in the progression of different cancers. R-ketorolac, their lead candidate, is a first-in-class Rac1 inhibitor that shows both clinical and non-clinical evidence of efficacy in ovarian cancer.